Investment Pitch media Logo  300 DPI Transparent BG (use).png
InvestmentPitch Media Video Discusses MindBio Therapeutics' Commencement of MB22001 Phase 2 Clinical Trial in World's First Take-Home Microdosing Study for Patients with Depression
August 25, 2023 06:00 ET | InvestmentPitch Media & MindBio Therapeutics
VANCOUVER, British Columbia, Aug. 25, 2023 (GLOBE NEWSWIRE) -- MindBio Therapeutics (CSE:MBIO) (FSE:WF6), an Australia-based biotech/biopharma company creating novel and emerging treatments for...
Investment Pitch media Logo  300 DPI Transparent BG (use).png
InvestmentPitch Media Video Discusses MindBio Therapeutics’ Clinical Trials of LSD-Microdosing Reveals Significant Positive Impact on Quality of Sleep
June 15, 2023 06:00 ET | InvestmentPitch Media & MindBio Therapeutics
VANCOUVER, British Columbia, June 15, 2023 (GLOBE NEWSWIRE) -- MindBio Therapeutics (CSE:MBIO) (FSE:WF6), a Melbourne, Australia-based leader in microdosing psychedelic medicines, announced a...
Investment Pitch media Logo  300 DPI Transparent BG (use).png
InvestmentPitch Media Video Discusses New CSE Listing MindBio Therapeutics, Pioneering Clinical Studies of Micro-Dosing of Psychedelic Medicines
May 08, 2023 06:00 ET | InvestmentPitch Media & MindBio Therapeutics
VANCOUVER, British Columbia, May 08, 2023 (GLOBE NEWSWIRE) -- MindBio Therapeutics (CSE:MBIO) is one of the latest new listings on the Canadian Securities Exchange. Based in Melbourne, Australia,...